GLP-1 Cost & Insurance: What You Actually Pay in 2026 (Medicare, Self-Pay & Savings)

Key takeaways

• List prices ($1,000 to $1,350/month) are not what most patients pay. Manufacturer savings cards bring the cost to $25 per fill for commercially insured patients. Without insurance, LillyDirect sells Zepbound at $299 to $449/month and NovoCare offers Wegovy starting at $199/month.
• The Medicare GLP-1 Bridge program starts July 1, 2026, offering FDA-approved GLP-1 medications for weight loss at a $50 monthly copay for eligible Part D beneficiaries. It runs through December 2027.
• Only 13 state Medicaid programs cover GLP-1 for obesity as of January 2026. The BALANCE model (CMS) allows additional states to opt in starting May 2026.
• The oral Wegovy pill (oral semaglutide 25 mg, FDA-approved December 2025) is available through NovoCare at $149 to $299/month cash pay depending on dose, making it the cheapest FDA-approved needle-free GLP-1 option.
• For understanding what these drugs actually do, see what is GLP-1. For weight loss data, see GLP-1 weight loss.

How much does GLP-1 medication actually cost?

It depends entirely on how you pay. The list price (what the manufacturer charges before any discounts) runs $1,000 to $1,350 per month for brand-name GLP-1 weight loss drugs. But list price is like a car's MSRP: it is the starting number, not the final price. With insurance coverage, a savings card, or a manufacturer direct program, the actual cost can be $25 to $449 per month. Without any of those, you pay full retail, which is over $12,000 per year.

The savings card programs from Novo Nordisk and Eli Lilly can bring commercially insured patients down to $25 per monthly fill, subject to monthly and annual caps. The cards require that your insurance already covers the drug; they reduce the copay, not the drug's price. If your insurance does not cover the drug, the savings card does not apply. That is why the cash-pay manufacturer programs (NovoCare and LillyDirect) matter so much for uninsured or underinsured patients.

What is the cheapest GLP-1 without insurance?

The cheapest FDA-approved GLP-1 without insurance is the oral Wegovy pill at $149 per month for the starter dose through NovoCare Pharmacy, Novo Nordisk's direct cash-pay program. For injectables, Wegovy injection starts at $199 per month (NovoCare) and Zepbound starts at $299 per month (LillyDirect). These manufacturer direct prices are dramatically lower than retail pharmacy prices.

LillyDirect sells Zepbound in single-dose vials: $299 per month for the 2.5 mg starting dose, $399 for 5 mg, and $449 for 7.5 to 15 mg doses, but only if you refill within 45 days of your previous delivery. Miss that window and prices revert to $599 to $1,049 depending on dose. LillyDirect ships directly to your home or offers pickup at participating Walmart pharmacies. In February 2026, Lilly also introduced multi-dose KwikPen devices through LillyDirect at $299 to $449 per month.

NovoCare Pharmacy offers Wegovy injection at $199 to $349 per month for new self-pay patients, and the Wegovy pill at $149 to $299 per month depending on dose. The starter dose promotional pricing for the pill ($149) runs through at least August 2026.

GoodRx and SingleCare discount cards can reduce retail prices, but they rarely beat the manufacturer direct programs. GoodRx typically brings Zepbound down to around $900 to $1,050 and Wegovy to about $1,100 to $1,300, far above LillyDirect and NovoCare pricing.

How to get GLP-1 covered by insurance

Step one: check your plan's formulary (covered drug list) to see if Wegovy or Zepbound is listed. Step two: if it is listed, your prescriber will need to submit a prior authorization showing you meet criteria (typically BMI 30+ or BMI 27+ with a comorbidity, documented in your medical record). Step three: if prior authorization is denied, appeal. Denial overturn rates for GLP-1 obesity medications have improved as clinical evidence has strengthened.

Most commercial insurance plans that cover GLP-1 for weight loss require prior authorization documenting: BMI at or above 30 (or 27 with a weight-related condition like hypertension, type 2 diabetes, dyslipidemia, or sleep apnea), and in some cases, documented prior attempts at lifestyle modification. Some plans require a 6-month documented history of diet and exercise attempts before approving GLP-1 coverage.

If your employer's plan excludes anti-obesity medications entirely (common in self-insured plans), your options are: the cash-pay manufacturer programs described above, asking your HR department whether the exclusion can be reconsidered (especially if your employer is large enough to modify the plan), or using the medication under a different indication (for example, Ozempic for type 2 diabetes, if applicable).

Prior authorization denial rates for GLP-1 obesity prescriptions have been high, and industry reporting through 2024 put them well above half of requests in some plans. Denial rates appear to be easing as the clinical evidence base strengthens. If your first request is denied, appeal with a letter of medical necessity from your prescriber. Include your BMI history, comorbidities, and relevant clinical trial data. Many denials are overturned on appeal.

Does Medicare cover GLP-1 for weight loss?

Not yet through standard Part D, but a new pathway opened in 2026. Federal law has historically prohibited Medicare Part D from covering drugs used for weight loss. The Treat and Reduce Obesity Act (TROA), which would permanently lift that prohibition, has bipartisan support but has not passed Congress as of mid-2026.

In the meantime, CMS (Centers for Medicare & Medicaid Services) created two demonstration programs:

Medicare GLP-1 Bridge (July 2026 to December 2027): A short-term program providing Medicare Part D beneficiaries access to select FDA-approved GLP-1 medications for obesity at a $50 monthly copay. Beneficiaries must be enrolled in a Part D plan and meet clinical criteria (BMI 30+ or BMI 27+ with a weight-related condition). The Bridge covers Wegovy, Zepbound, and Saxenda.

BALANCE Model (2027+): A longer-term demonstration program that aims to integrate GLP-1 coverage into Medicare Part D permanently, with a requirement that beneficiaries participate in lifestyle modification programs. CMS will negotiate drug pricing with manufacturers. State Medicaid agencies can join starting May 2026; Medicare Part D plans in January 2027.

Medicare does already cover GLP-1 for some non-weight-loss indications: Part D covers Ozempic and Mounjaro for type 2 diabetes, and Wegovy received a new indication for cardiovascular risk reduction in patients with established heart disease and obesity. If you have Medicare and one of these conditions, your prescriber may be able to get coverage through existing Part D pathways.

Does Medicaid cover GLP-1?

In most states, no. As of January 2026, only 13 state Medicaid programs cover GLP-1 medications for the treatment of obesity under fee-for-service. Federal law allows states to exclude weight-loss drugs from Medicaid formularies, and most do. Coverage for GLP-1 as a diabetes treatment is required because the drugs are FDA-approved for that indication.

The CMS BALANCE model offers states a path to expand coverage: states can opt into the model between May 2026 and January 2027, and CMS will negotiate lower drug pricing with manufacturers on behalf of participating states. The GENEROUS (Generating Cost Reductions for U.S. Medicaid) model, launched January 2026, is a related initiative aimed at reducing Medicaid drug costs.

Which states cover GLP-1 for obesity changes frequently. The Kaiser Family Foundation (KFF) maintains an updated tracker. Key states with coverage as of early 2026 include California, New York, and a handful of others. Four states had eliminated obesity drug coverage entirely. If you are on Medicaid and want GLP-1 for weight loss, check your state's current formulary and ask your prescriber about the diabetes indication if applicable.

Costco GLP-1 pricing: is it cheaper?

Costco pharmacy sometimes offers lower retail prices on GLP-1 medications than other retail pharmacies, but the savings are modest compared to manufacturer direct programs. You do not need a Costco membership to use the pharmacy (federal law requires pharmacies to serve non-members). But Costco's GLP-1 prices typically run $900 to $1,100 per month for Zepbound and similar ranges for Wegovy, well above LillyDirect's $299 to $449 and NovoCare's $199 to $349.

The most cost-effective approach: check manufacturer direct programs first (LillyDirect, NovoCare), then check insurance coverage and savings cards, then compare retail pharmacies including Costco only if the manufacturer options do not work for your situation.

Ro, Hers, and Noom GLP-1 costs compared

Online telehealth platforms like Ro, Hers (Hims & Hers), and Noom Med bundle prescriber consultations with GLP-1 medication at monthly program fees. Pricing varies: Ro starts at $149 per month for compounded semaglutide (not FDA-approved as a finished product), Hers ranges from $149 to $299, and Noom Med includes behavioral support with medication access. These platforms primarily offered compounded GLP-1 products, which are facing increasing FDA regulatory scrutiny in 2026.

An important distinction: compounded semaglutide and tirzepatide are custom-mixed versions of the active ingredient made by compounding pharmacies. They are not FDA-approved as finished products. The FDA issued over 80 warning letters to companies marketing compounded GLP-1 products with misleading claims in 2025-2026. If you go through a telehealth platform, verify whether you are receiving FDA-approved brand-name medication or a compounded version, and understand the regulatory risks.

For patients who want FDA-approved medication through an online prescriber, several platforms now offer consultations leading to prescriptions for brand-name Wegovy or Zepbound, which you then fill through insurance, LillyDirect, or NovoCare. The consultation fee is typically $50 to $150 on top of the medication cost.

GLP-1 pill cost vs injection cost

The oral Wegovy pill (semaglutide 25 mg tablet, FDA-approved December 2025) is positioned as a lower-cost needle-free entry point. NovoCare offers the pill at $149 per month for the starter dose through at least August 2026, making it the cheapest FDA-approved GLP-1 option for cash-pay patients. The injectable Wegovy starts at $199 per month through the same program.

For insured patients, copays for the pill and injection should be similar once both are on formulary. The clinical efficacy is comparable: the OASIS 4 trial showed 13.6% weight loss with the oral 25 mg tablet versus 14.9% for the injection in STEP 1. The daily pill trades the convenience of once-weekly injection for the freedom of no needles, but adds dosing constraints (empty stomach, limited water, 30-minute food restriction). For full clinical data, see our GLP-1 weight loss guide.

How to save money on GLP-1: a step-by-step approach

The optimal cost-reduction strategy depends on your insurance status. Some patients also ask about stretching a prescription with lower doses, which saves money but has no trial support. Here is the decision tree most obesity medicine specialists recommend:

What insurance covers GLP-1 for weight loss?

Most major commercial insurers (Blue Cross Blue Shield, United Healthcare, Aetna, Cigna) have plans that cover GLP-1 for weight loss, but coverage varies by specific plan, employer, and state. Self-insured employer plans (covering about 65% of commercially insured Americans) can choose to exclude anti-obesity medications, and many do to control costs. The best way to check: call the number on the back of your insurance card and ask specifically about Wegovy and Zepbound coverage for weight management.

Coverage has been expanding. The clinical trial evidence is now so strong (STEP, SURMOUNT, SELECT trials) that more payers are adding GLP-1 coverage. The SELECT trial's cardiovascular benefit data (20% MACE reduction) has been particularly influential in changing payer attitudes, because preventing heart attacks and strokes saves money long-term. Some insurers now cover Wegovy specifically for cardiovascular risk reduction in patients with established heart disease and obesity, even when their weight-loss-only formulary excludes it.

How much does Wegovy cost per month?

Wegovy's list price is approximately $1,350 per month for the 2.4 mg maintenance dose. With commercial insurance that covers it plus the manufacturer savings card, your out-of-pocket cost can be as low as $25 per fill. Through NovoCare's direct cash-pay program, Wegovy injection costs $199 to $349 per month depending on dose. The new Wegovy pill costs $149 to $299 per month through NovoCare.

Novo Nordisk's savings card provides up to $500 off per monthly prescription, with a maximum annual benefit. It requires that you have commercial insurance coverage. Patients on Medicare, Medicaid, TRICARE, or other government programs are not eligible for the savings card but may qualify for the Novo Nordisk Patient Assistance Program (PAP), which provides the medication free to qualifying low-income patients.

How much does Zepbound cost per month?

Zepbound's list price is approximately $1,060 per month. With commercial insurance plus the Zepbound savings card, the cost is as low as $25 per fill. Through LillyDirect, cash-pay prices are $299 per month (2.5 mg), $399 (5 mg), and $449 (7.5 to 15 mg), provided you refill within 45 days. Multi-dose KwikPen devices are also available at $299 to $449.

Eli Lilly has been more aggressive than Novo Nordisk on pricing accessibility. LillyDirect launched in early 2024 and has cut prices multiple times since. The introduction of multi-dose pens in February 2026 further reduced per-dose costs. Lilly also participates in the TrumpRx direct-to-consumer program at approximately $350 per month.

For detailed comparison of all GLP-1 weight-loss results, see GLP-1 weight loss. For understanding side effects, see GLP-1 side effects.

Is there a generic GLP-1?

No. As of mid-2026, no generic versions of semaglutide or tirzepatide are FDA-approved. Both drugs are protected by extensive patent portfolios. Generic semaglutide is not expected until at least 2031 to 2033, based on current patent expiration timelines. Compounded versions of semaglutide existed (and were heavily marketed through telehealth platforms), but the FDA is cracking down on compounders making GLP-1 products now that the drug shortage has ended.

The distinction matters: "compounded" is not the same as "generic." A generic drug goes through an FDA approval process (ANDA filing) demonstrating bioequivalence to the branded product. Compounded drugs are custom-mixed by compounding pharmacies without FDA approval of the finished product. The quality, sterility, potency, and consistency of compounded drugs can vary. The FDA issued over 80 warning letters to GLP-1 compounders in 2025-2026 for making false or misleading claims, including suggesting their products are equivalent to FDA-approved drugs. A separate category sits further outside the system entirely: OTC patches marketed as GLP-1 alternatives contain no prescription medication at all.

How to appeal an insurance denial for GLP-1

If your prior authorization is denied, you have the right to appeal. The process varies by insurer, but the general steps are consistent: request the denial in writing (the insurer must provide the specific reason), have your prescriber write a letter of medical necessity that addresses the denial reason directly, include supporting clinical data (STEP, SURMOUNT, SELECT trial results), and submit within the appeal deadline (typically 60 to 180 days depending on the plan).

A strong letter of medical necessity should include: your BMI history over at least 12 months, documentation of weight-related comorbidities (hypertension, type 2 diabetes or prediabetes, dyslipidemia, sleep apnea), prior weight-loss attempts and their outcomes, the specific clinical trial data supporting the requested medication, and a statement that the medication is medically necessary (not cosmetic). Many prescribers have templates for these letters.

For employer-sponsored self-insured plans, you may also have the option to request an independent external review. Under the Affordable Care Act, all non-grandfathered plans must offer external review for adverse benefit determinations. The external reviewer is an independent medical professional, not an employee of the insurance company.

Persistence matters. Some patients report success on second or third appeals, especially when the clinical case is strengthened with additional documentation. If your BMI is borderline (27 to 30), documenting comorbidities thoroughly can make the difference.

GLP-1 cost over time: what a full year costs

A full year of GLP-1 treatment costs $300 to $16,000+ depending on your access pathway. At the best case ($25 per month with insurance and savings card), the annual cost is $300. Through LillyDirect at $299 to $449 per month, the annual cost is $3,588 to $5,388. At full retail with no discount, it is $12,000 to $16,000 per year.

Context matters for evaluating these costs. Obesity-related healthcare spending averages $1,861 per person per year above healthy-weight peers, in 2019 dollars, according to the CDC. For type 2 diabetes, the American Diabetes Association estimates $12,022 per person per year in medical expenditure attributable to the disease. Cardiovascular events add substantially more. GLP-1 medications that prevent or delay these outcomes can be cost-effective even at higher price points, which is the argument payers are increasingly accepting.

The cost trajectory is also favorable. Prices have dropped substantially since 2023 (when Wegovy launched at $1,349 with no cash-pay alternative), and further reductions are expected as competition increases and Medicare coverage expands. Patients starting treatment today are entering a market with more affordable options than existed even 12 months ago.

Patient assistance programs for GLP-1

Both Novo Nordisk and Eli Lilly operate patient assistance programs (PAPs) that provide GLP-1 medication free of charge to qualifying low-income patients. The programs have income requirements (typically 200 to 400% of the federal poverty level) and exclude patients with certain types of insurance coverage.

Novo Nordisk Patient Assistance Program (PAP): Provides Wegovy, Ozempic, and Saxenda free to patients without insurance who meet income criteria. Application requires proof of income and a prescription from a licensed provider. Processing takes 2 to 4 weeks. Contact NovoCare at 1-888-NOVO-444.

Eli Lilly Solutions Center: Provides Zepbound and Mounjaro to qualifying patients. Income-based eligibility. Similar documentation requirements. Contact 1-800-LillyRx.

PAN Foundation Obesity Fund: An independent nonprofit that provides up to $1,000 in grants toward obesity medication costs. Open to patients with commercial insurance facing high out-of-pocket costs. Funds are limited and reopen periodically. Check availability at panfoundation.org.

These programs exist specifically for patients who cannot afford the medication through any other pathway. If you have exhausted insurance options, manufacturer cash-pay programs are too expensive, and your income qualifies, these programs can provide the medication at no cost.

Will GLP-1 prices come down?

Yes, and they already have. Multiple forces are driving prices lower. Manufacturer competition between Novo Nordisk and Eli Lilly has produced direct cash-pay programs that did not exist before 2024. The Medicare GLP-1 Bridge creates government negotiating use. New oral formulations (Wegovy pill, upcoming oral tirzepatide) are cheaper to manufacture than injectables. And the political pressure from both parties, fueled by the enormous public interest in GLP-1 medications, makes continued high pricing increasingly untenable.

Generic semaglutide remains 5 to 7+ years away based on patent timelines. But the effective cost to patients is already far below list price. The average insured patient with savings card pays $25 per month today, and the average uninsured patient can access FDA-approved medication for $149 to $449 per month through manufacturer programs. Three years ago, the equivalent numbers were $150+ per month insured and $1,000+ uninsured. The trend is unmistakable.

The most impactful upcoming change: if the BALANCE model transitions to permanent Medicare Part D coverage in 2028 as planned, approximately 50 million Medicare beneficiaries will gain access to GLP-1 for obesity treatment. That volume will fundamentally reshape the drug's economics. Before committing to a treatment, it is worth understanding what these medications do and the nutritional gaps they create.

GLP-1 cost for non-diabetic patients

Non-diabetic patients face the same list prices as diabetic patients but may encounter different insurance pathways. Wegovy and Zepbound are FDA-approved for weight management regardless of diabetes status, but many insurance plans have stricter prior authorization requirements for weight-loss indications than for diabetes. Some plans cover Ozempic for diabetes but not Wegovy for weight loss, even though both contain semaglutide.

The workaround many prescribers use: if a non-diabetic patient also has a comorbidity that a GLP-1 drug treats (cardiovascular disease for Wegovy, sleep apnea for Zepbound), the prescriber can request coverage under that indication. Zepbound received FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024, and Wegovy gained a cardiovascular risk reduction indication for patients with established heart disease and obesity. These secondary indications sometimes face less prior authorization friction than the primary weight-loss indication.

For non-diabetic patients whose insurance denies coverage entirely, the cash-pay options are the same as for everyone else: NovoCare ($149 to $349/month), LillyDirect ($299 to $449/month), or patient assistance programs if income-eligible. Your diabetes status does not affect manufacturer direct pricing.

Cheapest way to get GLP-1 online

The cheapest legitimate path to a GLP-1 prescription online: consult a licensed prescriber (telemedicine visit, $50 to $150), get a prescription for brand-name Wegovy or Zepbound, and fill it through NovoCare or LillyDirect at their cash-pay prices. Total first-month cost: roughly $200 to $500 (consultation + medication). This gets you an FDA-approved product prescribed by a real doctor, filled through the manufacturer's own program.

Several telehealth platforms (Ro, Noom Med, Found, Calibrate) offer GLP-1 prescribing with bundled monthly fees that include consultations, medication, and sometimes behavioral support. Monthly costs range from $149 to $399 depending on the platform and medication. When evaluating these services, check whether the medication is FDA-approved brand-name (Wegovy, Zepbound) or compounded. Compounded GLP-1 products are not FDA-approved as finished drugs and face increasing regulatory restrictions.

Do not buy GLP-1 medications from unregulated international websites, social media sellers, or sources that do not require a prescription. Counterfeit and substandard GLP-1 products are a documented safety risk. The FDA and WHO have both issued alerts about falsified semaglutide products found in multiple countries.

Foundayo (orforglipron) pricing: the next cost disruptor?

Foundayo (orforglipron) is Eli Lilly's small-molecule oral GLP-1 receptor agonist, FDA-approved on April 1, 2026 for chronic weight management in adults with obesity or overweight with a weight-related condition. A type 2 diabetes submission is planned but not yet approved. Unlike semaglutide (a large peptide requiring specialized absorption technology), orforglipron is a small molecule that absorbs more reliably through the GI tract, can be taken with food, and is cheaper to manufacture. Lilly launched Foundayo through LillyDirect at $149 per month, the most affordable branded GLP-1 on the market.

This matters for the cost landscape because small-molecule drugs are inherently less expensive to produce at scale than biologic peptides. If Foundayo's clinical outcomes hold up in real-world use (the Phase 3 ATTAIN-1 trial showed 11.2% mean weight loss at 72 weeks on the 36 mg dose, or 12.4% among participants who stayed on treatment), it could become the go-to affordable GLP-1 option and put downward pressure on Wegovy and Zepbound pricing. For patients who have been priced out of GLP-1 treatment, the arrival of a $149 per month oral option from a major manufacturer is the most significant access development since the LillyDirect launch.

The true cost of not treating obesity

The annual excess healthcare cost of obesity is approximately $1,861 per person compared with healthy-weight adults, in 2019 dollars (CDC). For type 2 diabetes, the ADA puts attributable annual spending at $12,022 per person. Cardiovascular events, cancer, and joint replacement add further cost on top of that. Obesity is associated with 13 types of cancer, increased surgical complication rates, lost work productivity ($1,784 per obese worker annually), and reduced life expectancy of 5 to 14 years depending on severity.

This context matters when evaluating whether GLP-1 medication is "too expensive." A $300 annual cost (insured + savings card) or even a $5,000 annual cost (LillyDirect cash pay) must be weighed against the downstream medical costs it prevents. The SELECT trial demonstrated that semaglutide reduces major adverse cardiovascular events by 20% in patients with obesity and established heart disease. That reduction in heart attacks and strokes represents enormous long-term cost avoidance for both patients and the healthcare system.

This is the argument driving insurer and Medicare coverage expansion. The question has shifted from "is it too expensive to cover GLP-1?" to "is it too expensive not to?" As clinical data accumulates showing that GLP-1 medications reduce the incidence and severity of the most expensive chronic diseases, payers are recognizing that proactive treatment of obesity saves money compared to treating its downstream consequences.

Frequently asked questions

What is the cheapest way to get GLP-1?

For commercially insured patients: Wegovy or Zepbound with a manufacturer savings card at $25 per fill. For uninsured patients: the Wegovy pill through NovoCare at $149 per month (starter dose). For Medicare beneficiaries: the GLP-1 Bridge program at $50 per month starting July 2026.

How much is GLP-1 per month?

List price: $1,000 to $1,350. With insurance + savings card: as low as $25. Cash pay through manufacturer programs: $149 to $449 depending on drug and dose. Retail without any discount: $900 to $1,640.

Can you get GLP-1 without insurance?

Yes. LillyDirect (Zepbound) and NovoCare (Wegovy) sell directly to patients without requiring insurance. Prices range from $149 to $449 per month depending on the drug and dose. No prior authorization needed for cash-pay purchases.

Does GoodRx work for GLP-1?

GoodRx provides modest discounts at retail pharmacies, but the savings rarely match manufacturer direct programs. GoodRx typically brings GLP-1 prices to $900 to $1,100 per month, while LillyDirect and NovoCare offer $149 to $449. Use GoodRx only if manufacturer programs are unavailable.

Will GLP-1 ever be affordable?

Prices are trending down. LillyDirect has cut Zepbound cash prices multiple times. The Wegovy pill launched at $149 to $299 (lower than the injection). Medicare coverage is arriving via the GLP-1 Bridge. Generic versions remain 5 to 7+ years away, but manufacturer competition and government pressure are driving prices lower faster than the patent timeline alone would suggest.

Watch: GLP-1 cost and insurance explained

Published research cited in this article

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not intended as medical advice. Drug pricing changes frequently; verify current prices directly with manufacturers, pharmacies, and your insurance provider. GLP-1 receptor agonists are prescription medications. Consult your healthcare provider to discuss treatment options.

GLP-1 Cost 2026

Metric	Value
List price	$900-1,350/mo
LillyDirect Zepbound	$299/mo
Orforglipron	$149/mo
Medicare Bridge	$50/mo
Source: CMS.gov; Eli Lilly Direct pricing 2026